Akoya Biosciences

MARLBOROUGH, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in three upcoming investor conferences.…

MARLBOROUGH, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in two upcoming investor conferences. UBS Genomics 2.0…

The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted oncology agent for solid cancers The…

MARLBOROUGH, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, will present for the first time, data generated using its proprietary RNA chemistry, which enables whole-slide…

-Company previews an integrated suite of solutions, including the new PhenoCycler™-Fusion System for unbiased spatial discovery, at unprecedented speeds -Innovations include a novel spatial transcriptomics chemistry and universal protein…

MARLBOROUGH, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, and PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, today announced a…

MARLBOROUGH, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that the Phenoptics™ mIF solution was used in a multi-site study to demonstrate and validate an…

Investigators at Johns Hopkins University (JHU) used AstroPath to identify and validate biomarkers for accurate prediction of long-term response to immune checkpoint inhibitors in advanced melanoma AstroPath combines JHU’s famed 3D sky…